Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Zixin Wang *Engineering Research Center of Cell & Therapeutic Antibody, Shanghai Frontiers Science Center of Drug Target Identification and Delivery, Shanghai Key Laboratory for Antibody-Drug Conjugates with Innovative Target, National Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Zeen Lv *Eye Center, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Hangzhou, China.
Yuxuan GeShanghai Jiao Tong University Affiliated Sixth People's Hospital South Campus, Shanghai, China.
Ruiyang XueEngineering Research Center of Cell & Therapeutic Antibody, Shanghai Frontiers Science Center of Drug Target Identification and Delivery, Shanghai Key Laboratory for Antibody-Drug Conjugates with Innovative Target, National Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Fang WuEye Center, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Hangzhou, China.
Haijie HanEye Center, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Hangzhou, China. hanhj90@zju.edu.cn.ORCID http://orcid.org/0000-0002-0936-2791
Yin WangEngineering Research Center of Cell & Therapeutic Antibody, Shanghai Frontiers Science Center of Drug Target Identification and Delivery, Shanghai Key Laboratory for Antibody-Drug Conjugates with Innovative Target, National Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China. yinwang@sjtu.edu.cn.ORCID http://orcid.org/0000-0001-6729-7230
Funding
National Natural Science Foundation of China (National Science Foundation of China) 22105126National Natural Science Foundation of China (National Science Foundation of China) 22375128National Natural Science Foundation of China (National Science Foundation of China) 82271064National Natural Science Foundation of China (National Science Foundation of China) 82572387Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) LR23H120001Science and Technology Department of Zhejiang Province 2024C03073
6 · The paper itself
Abstract
The management of ocular surface inflammation, particularly in conditions like dry eye disease (DED), remains challenging due to multiple pathogenic causes and ocular barriers. Traditional eye drops usually provide transient and partial symptom relief, necessitating combined therapies to break the vicious cycle of oxidative stress and inflammation. To surmount these limitations, a polyphenol-based eye drop is developed via the self-polymerization of rosmarinic acid in the presence of hyaluronic acid, followed by co-assembly with cerium ions to afford monodispersed RHC NPs. To enhance the ocular retention efficiency, thiol groups are further decorated on NPs (termed as s-RHC NPs). In two mouse models of DED, topical administration of s-RHC NPs leads to comprehensive relief of symptoms, including inflammatory response suppression, corneal epithelial defect repair, and tear secretion recovery. We envision that this work might facilitate the treatment of DED and inspire the design of polyphenol-based nanoparticles via a self-polymerization strategy.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Self-polymerized polyphenol-based platform for the management of dry eye pathogenesis. · full record | OpenQuestion